Vertex, Inc. (VERX)
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-09-04
$13.77-0.07%
Close 2026-09-04 · 1-day change
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-09-04
Intact: The reason to own it still holds.
Vertex is raising revenue guidance to about $825 million for 2026. Sales grew from $177 million in 2025-Q1 to $197 million in 2026-Q1. The company is focusing on AI to improve products and cut costs. Share buybacks and FDA approvals support growth.
Vertex is still loss-making and faces risks from workforce cuts. AI transformation progress is mixed at 40%. If revenue growth slows below 7%, the turnaround may stall.
The stock trades about 25% below consensus price levels. Analysts expect roughly 13% revenue growth. Our view aligns with this growth but sees risk in execution and profitability.
Breaks if: Progress score remains below 40% or declines
Advance the AI-First strategy to improve engineering and customer-delivery workflows and accelerate product innovation and growth.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as VERX is focused on transforming its operations through AI and improving operational efficiency. The current thesis state is cautious, with recent financial performance being weak compared to peers.
The market appears to have priced in a justified valuation, with a low expectations gap. This suggests that investors are not overly optimistic about future growth, but they are also not expecting significant declines.
Management's focus on operational efficiency is showing some positive results, as indicated by improved operating income and revenue growth. However, the recent financial performance has been weak, which could pose risks in the near term.
The long-term thesis hinges on several factors, including the potential for the Fed to cut rates, which could benefit tech stocks like VERX. Additionally, strong performance from sector leaders could provide momentum for VERX, while any cuts to guidance would negatively impact sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis. However, a legal ruling against Vertex's patents for a cystic fibrosis drug poses a threat. The company's focus on AI-enabled transformation remains a positive factor.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Management highlights the AI-First strategy improving engineering and customer workflows and strengthening leadership to accelerate innovation and growth. This aligns with the operational focus and transformation efforts described, showing delivering progress on AI-enabled transformation.
“Our 'AI-First' strategy is beginning to improve the speed and efficiency of selected engineering and customer-delivery workflows.”
“In April, we announced our Value Creation Plan to transform Vertex into a more effective, AI-leading organization.”
Breaks if: Efficiency progress score stays below 40% or worsens
Enhance operational efficiency to align resources with long-term strategic priorities.
Breaks if: Full-year 2026 revenue falls below $823.5 million
Raise revenue guidance for the full-year 2026 to $823.5M-$831.5M.
Overall, the outlook for VERX is mixed, with a focus on improving fundamentals and external market conditions playing a crucial role. Not investment advice.